March 2, 2017 – A recent supplement of the journal focuses on the work of the group, which is facilitated by the DCRI.
Clinical Infectious Diseases, one of the most widely cited journals in its field, has devoted an entire supplement to the Antibacterial Resistance Leadership Group (ARLG).
The ARLG develops, designs, implements, and manages a clinical research agenda to increase knowledge of antibacterial resistance. It aims to advance research by building transformational trials that will change clinical practice and reduce the impact of antibacterial resistance and antimicrobial resistance. The ARLG is facilitated by the DCRI and works under the centralized leadership of an executive committee and two principal investigators: the DCRI’s Vance Fowler, MD, MHS (pictured), and Henry ‘Chip’ Chambers, MD, of the University of California, San Francisco.
The issue of Clinical Infectious Diseases includes articles from ARLG members and others describing many of the group’s current projects.
“The ARLG is an example of a successful public–private partnership that has driven research on the wide array of issues related to antibiotic resistance, and it is well positioned to continue playing a critical role in the United States and through global collaborations with other groups,” writes Barbara E. Murray of the University of Texas Health Sciences Center and Amanda Jezek of the Infectious Diseases Society of America in their introduction to the issue.